Sugi Predict

Sugi Predict / Compounds / SCHEMBL858202

SCHEMBL858202

SCHEMBL858202

CC(=O)c1ccc(-c2ccnc3[nH]ccc23)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 5/20 0.74
▸ CHUK O15111 4/20 0.74
▸ NEK1 Q96PY6 4/20 0.66
▸ DAPK3 O43293 1/20 0.60
▸ JAK2 O60674 1/20 0.60
▸ PRKD3 O94806 1/20 0.60
▸ MAP4K4 O95819 1/20 0.60
▸ PAK4 O96013 1/20 0.60
▸ CSF1R P07333 1/20 0.60
▸ RET P07949 1/20 0.60
▸ IGF1R P08069 1/20 0.60
▸ FGFR1 P11362 1/20 0.60
▸ PRKACA P17612 1/20 0.60
▸ FLT1 P17948 1/20 0.60
▸ LTK P29376 1/20 0.60
▸ GRK5 P34947 1/20 0.60
▸ KDR P35968 1/20 0.60
▸ MAP2K2 P36507 1/20 0.60
▸ MAPK8 P45983 1/20 0.60
▸ CSNK1A1 P48729 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4791827 0.87 IKBKB (0.76) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL4877341 0.86 IKBKB (0.71) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL4791756 0.86 IKBKB (0.71) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL29854685 0.86 IKBKB (0.71) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL4791333 0.85 IKBKB (1.00) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL4790487 0.85 IKBKB (0.69) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL856859 0.85 PRKCI (0.76) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL1718374 0.83 CIT (0.71) IKBKBCHUKCIT
SCHEMBL4793711 0.82 NEK1 (0.77) IKBKBCHUKNEK1DAPK3JAK2
SCHEMBL12346408 0.82 IKBKB (0.70) IKBKBCHUKNEK1DAPK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US claimed
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 — — US disclosed
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 — — US disclosed
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2016-06-23 — — US disclosed
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2016-06-23 — — US disclosed
US-20150290200-A1 INTRACELLULAR KINASE INHIBITORS PHARMACYCLICS INC (US) 2015-10-15 — — US disclosed
US-20150290200-A1 INTRACELLULAR KINASE INHIBITORS PHARMACYCLICS INC (US) 2015-10-15 — — US disclosed
US-20150290200-A1 INTRACELLULAR KINASE INHIBITORS PHARMACYCLICS INC (US) 2015-10-15 — — US disclosed
US-20150290205-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2015-10-15 — — US disclosed
US-20150290205-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2015-10-15 — — US disclosed
EP-1979353-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2008-10-15 — — EP disclosed
US-20070293499-A1 Intracellular Kinase Inhibitors MANNKIND CORPORATION (US) 2007-12-20 — — US disclosed
US-20070293499-A1 Intracellular Kinase Inhibitors MANNKIND CORPORATION (US) 2007-12-20 — — US disclosed
US-20070293499-A1 Intracellular Kinase Inhibitors MANNKIND CORPORATION (US) 2007-12-20 — — US disclosed
WO-2007136790-A2 INTRACELLULAR KINASE INHIBITORS MANNKIND CORPORATION (US) 2007-11-29 — — WO disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US disclosed
US-20070208053-A1 Fused heterobicyclic kinase inhibitors OSI PHARMACEUTICALS, INC. 2007-09-06 — — US disclosed
WO-2007084667-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI PHARMACEUTICAL, INC. (US) 2007-07-26 — — WO disclosed
WO-2007084667-A2 FUSED HETEROBICYCLIC KINASE INHIBITORS OSI PHARMACEUTICAL, INC. (US) 2007-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293499-A1 Intracellular Kinase Inhibitors PI4KB, BTK, LTK IKBKB 107/4885CHUK 95/4885NEK1 157/4885
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 IKBKB 387/4885CHUK 210/4885NEK1 223/4885
US-20150290205-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 IKBKB 387/4885CHUK 210/4885NEK1 223/4885
US-20150290200-A1 INTRACELLULAR KINASE INHIBITORS PI4KB, BTK, LTK IKBKB 107/4885CHUK 95/4885NEK1 157/4885
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 IKBKB 387/4885CHUK 210/4885NEK1 223/4885
US-20070208053-A1 Fused heterobicyclic kinase inhibitors MAP2K5, MAP2K7, MAP2K2 IKBKB 138/4885CHUK 31/4885NEK1 870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.